Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2014

View Archived Issues

Biomarkers may identify patients with dengue with warning signs

Phase II results indicate cutamesine may be more effective in moderate-to-severe stroke

Pim kinase inhibitor found to sensitize SCLC cells to BH3 mimetic

Recombinant NDV-GM-CSF: a lead project from MedImmune's NDV oncolytic platform

Synthon initiates first-in-human study of HER2-targeted ADC SYD-985

Isis Pharmaceuticals earns milestone payment for advancing ISIS-BIIB3Rx

Oral JAK1 inhibitor shows dose-dependent activity in phase II psoriasis trial

Arcturus Therapeutics expands operations to support RNA drug discovery

Omeros reports data for OMS-721 derivative in experimental model of stroke

Leading BioSciences submits IND for drug to treat Ebola-related shock, multiorgan failure

New biomarkers to improve sensitivity and specificity of diagnosing endometriosis

Cantrixil shows activity in animal model of paclitaxel-resistant ovarian cancer

Deutetrabenazine classified as orphan drug by the FDA

AstraZeneca reviews highlights of third quarter 2014

Sage Therapeutics discloses new GABA(A) receptor modulators

Pfizer patents novel PCSK9 inhibitors

Merck & Co. patent reports new HIV integrase inhibitors

New methyltransferase inhibitors designed by U.S. researchers

Lundbeck and Vernalis disclose novel LRRK2 inhibitors

IRCM to create spin-off company Liphorus Pharmaceuticals

Janssen Pharmaceutica patents novel NIK inhibitors for cancer

Perrigo to acquire Omega Pharma

Johnson & Johnson completes acquisition of Alios BioPharma

FDA committee votes against recommending approval of panobinostat

Phase I/II data for HepaStem in urea cycle disorders and Crigler-Najjar syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...